Hormonal
Dual GIP/GLP-1 receptor agonism (e.g., tirzepatide) yields superior glycemic control and body weight reduction compared to selective GLP-1 receptor agonists.
For patients with type 2 diabetes seeking maximum glucose and weight reduction, dual GIP/GLP-1 agonists (like tirzepatide) are clinically superior to selective GLP-1 agonists. This represents a shift from previous assumptions that GIP was therapeutically useless in diabetes.
The recent finding that GIP/GLP-1 receptor co-agonists like tirzepatide have superior efficacy compared to selective GLP-1 receptor agonists with respect to glycaemic control as well as body weight has renewed interest in GIP... Tirzepatide treatment led to more profound reductions in HbA1c (by approximately 2 %) and in body weight (often exceeding 10 kg on average).
Why this rating
Based on a review of clinical trial data (tirzepatide vs. dulaglutide/semaglutide) cited in the text, though specific trial IDs are referenced rather than raw data provided in this excerpt.
Source
The evolving story of incretins ( <scp>GIP</scp> and <scp>GLP</scp> ‐1) in metabolic and cardiovascular disease: A pathophysiological update
Michael A. Nauck et al. · Diabetes Obesity and Metabolism · 2021
DOI 10.1111/dom.14496
More from this paper
- GIP is the major physiological mediator of the incretin effect in healthy humans, contributing more to insulin secretion than GLP-1.Strong
- GIP promotes triglyceride storage in white adipose tissue and may contribute to ectopic fat accumulation (fatty liver) in mice, acting as an obesogenic hormone in this context.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →